

DAFTAR PUSTAKA

- Akkoca, Ayşe Neslin, *et al.* "TNM and Modified Dukes staging along with the demographic characteristics of patients with colorectal carcinoma." *International journal of clinical and experimental medicine* 7.9 (2014): 2828.
- Allemani, Claudia, *et al.* "Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)." *The Lancet* 385.9972 (2015): 977-1010.
- Ansari MA, Shaikh S, Muteeb G, Rizvi D, Shakil S, Alam A, Tripathi R, Ghazal F, Rehman A, Ali SZ, Pandey AK, Ashraf GM. Role of Matrix Metalloproteinases in Cancer. In: Ashraf GM, Sheikh IA, editors. *Advanced in Protein Chemistry*. USA: OMICS group ebook. 2013; 4-10.
- Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjänen, S., Syrjänen, K., Collan, Y., & Pyrhönen, S. (2010). MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. *Cancer Investigation*, 28(1), 38–43. <https://doi.org/10.3109/07357900802672761>
- Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjänen, S., Syrjänen, K., Collan, Y., & Pyrhönen, S. (2008). VEGF-1 Expression in Colorectal Cancer is Associated with Disease Localization, Stage, and Long-term Disease-specific Survival. *Anticancer Research*, 28(6B).

- Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A. B., & Maisonneuve, P. (2008). Smoking and colorectal cancer: a meta-analysis. *JAMA*, *300*(23), 2765–2778. <https://doi.org/10.1001/JAMA.2008.839>
- Bourboulia, Dimitra, and William G. Stetler-Stevenson. "Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion." *Seminars in cancer biology*. Vol. 20. No. 3. Academic Press, 2010.
- Brenner, H., Kloor, M., & Pox, C. P. (2014). Colorectal cancer. *The Lancet*, *383*(9927), 1490–1502. [https://doi.org/10.1016/S0140-6736\(13\)61649-9](https://doi.org/10.1016/S0140-6736(13)61649-9)
- Brown, Gordon T., and Graeme I. Murray. "Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis." *The Journal of pathology* *237.3* (2015): 273-281.
- Bruniciadi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Pollock RE. Schwartz's principles of surgery. 8th ed. New York: The McGraw – Hill Companier. 2017;1073 – 1075.
- Cabral-Pacheco, G. A., Garza-Veloz, I., Rosa, C. C. D. La, Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020). The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. *International Journal of Molecular Sciences*, *21*(24), 1–53. <https://doi.org/10.3390/IJMS21249739>
- Cross, A. J., Boca, S., Freedman, N. D., Caporaso, N. E., Huang, W. Y., Sinha, R., Sampson, J. N., & Moore, S. C. (2014). Metabolites of tobacco smoking and colorectal cancer risk. *Carcinogenesis*, *35*(7).

<https://doi.org/10.1093/CARCIN/BGU071>

Chu D, Zhao Z, Zhao Y, Li Y, Li J, Zheng J, *et al.* Matrix metalloproteinase-9 is associated with relapse and prognosis of patients cancer. *Ann Surg Oncol.* 2012; 19: 318-25.

Decock, J., Robert Paridaens, and S. Ye. "Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer." *Clinical genetics* 73.3 (2008): 197-211.

Degregori, J. (2013). Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age? *Oncogene*, 32(15), 1869–1875. <https://doi.org/10.1038/ONC.2012.281>

Deryugina, Elena I., and James P. Quigley. "Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature." *Matrix Biology* 44 (2015): 94-112.

Dharmaji, A.B., Lusikooy, R.E., "Analisis Perbedaan Derajat Kelangsungan Hidup (Survival Rate) Adenokarsinoma Kolorektal Di RSUP. Dr. Wahidin Sudirohusodo Makassar". Tesis. Makassar (2020) : Universitas Hasanuddin

Dharmayanti, Sri, *et al.* "Imunoekspresi Lgr5 dan E-cadherin sebagai Faktor Prediksi Metastasis ke Kelenjar Getah Bening Regional pada Adenokarsinoma Kolorektal." *Majalah Patologi Indonesia* 28.1 (2019): 50-55.

Dragutinović, V. V., Radonjić, N. V., Petronijević, N. D., Tatić, S. B., Dimitrijević, I. B., Radovanović, N. S., & Krivokapić, Z. V. (2011). Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as

- independent prognostic markers in patients with colorectal cancer. *Molecular and Cellular Biochemistry* 2011 355:1, 355(1), 173–178.
<https://doi.org/10.1007/S11010-011-0851-0>
- Dufour, Antoine, *et al.* "Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides." *Journal of Biological Chemistry* 285.46 (2010): 35944-35956.
- Eka Shinta, H., Gusti Alit Artha, I., & Saputra, H. (2019). Ekspresi Matriks Metalloproteinase-9 Berhubungan Positif dengan Kedalaman Invasi Adenokarsinoma Kolorektal. *Majalah Patologi Indonesia*, 28(2), 22–27.
<https://majalahpatologiindonesia.com/p/index.php/patologi/article/view/384>
- Fakhri, A., & Agus, S. (2017). Hubungan Ekspresi Matriks Metaloproteinase-9 dan Tingkat Kedalaman Invasi Adenokarsinoma Kolorektal Invasif. *Majalah Patologi Indonesia*, 26(3), 21–26.
<https://majalahpatologiindonesia.com/p/index.php/patologi/article/view/297>
- Farina, Antonietta Rosella, and Andrew Reay Mackay. "Gelatinase B/MMP-9 in tumour pathogenesis and progression." *Cancers* 6.1 (2014): 240-296.
- Fleming, Matthew, *et al.* "Colorectal carcinoma: Pathologic aspects." *Journal of gastrointestinal oncology* 3.3 (2012): 153.
- Gialeli, Chrisostomi, Achilleas D. Theocharis, and Nikos K. Karamanos. "Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting." *The FEBS journal* 278.1 (2011): 16-27.

- Gill, Sean E., and William C. Parks. "Matrix metalloproteinases and their inhibitors in turnover and degradation of extracellular matrix." *Extracellular matrix degradation*. Springer, Berlin, Heidelberg, 2011. 1-22.
- GLOBOCAN. 2020. *Cancer today*. International Agency for Research on Cancer. <http://gco.iarc.fr/>
- Gonzalez RS. WHO classification. PathologyOutlines.com website. <https://www.pathologyoutlines.com/topic/colontumorwhoclassification.html>. Accessed January 3rd, 2022
- Granados-Romero, Juan José, *et al.* "Colorectal cancer: a review." *Int J Res Med Sci* 5.11 (2017): 4667-4676.
- Gunasekaran, V., Ekawati, N. P., & Sumadi, I. W. J. (2019). Karakteristik klinikopatologi karsinoma kolorektal di RSUP Sanglah, Bali, Indonesia tahun 2013-2017. *Intisari Sains Medis*, 10(3), 552–556. <https://doi.org/10.15562/ism.v10i3.458>
- Hamilton SW., *et al.* "Colorectal cancer screening." *Journal of the National Comprehensive Cancer Network* 8.1 (2010): 8-61.
- Hamza, Amal H., Hadeer A. Aglan, and Hanaa H. Ahmed. "Recent Concepts in the Pathogenesis and Management of Colorectal Cancer." *Recent Advanced in Colon Cancer* (2017).
- Hassan, Muhammad Radzi Abu, *et al.* "Survival analysis and prognostic factors for colorectal cancer patients in Malaysia." *Asian Pacific Journal of Cancer Prevention* 17.7 (2016): 3575-3581.

- Hemminki, K., Santi, I., Weires, M., Thomsen, H., Sundquist, J., & Bermejo, J. L. (2010). Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. *BMC Cancer*, *10*. <https://doi.org/10.1186/1471-2407-10-688>
- Huang, X., Lan, Y., Li, E., Li, J., Deng, Q., & Deng, X. (2021). Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer. *The Journal of International Medical Research*, *49*(5). <https://doi.org/10.1177/03000605211012570>
- Hull, M. A., Rees, C. J., Sharp, L., & Koo, S. (2020). A risk-stratified approach to colorectal cancer prevention and diagnosis. *Nature Reviews Gastroenterology & Hepatology* 2020 17:12, *17*(12), 773–780. <https://doi.org/10.1038/s41575-020-00368-3>
- Hurst, N. G., Stocken, D. D., Wilson, S., Keh, C., Wakelam, M. J. O., & Ismail, T. (2007). Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. *British Journal of Cancer*, *97*(7), 971. <https://doi.org/10.1038/SJ.BJC.6603958>
- IARC (2019). Colorectal cancer screening. IARC Handb Cancer Prev. 17:1–300. Available from: <http://publications.iarc.fr/573>.
- Ihemelandu, Chukwuemeka *et al.* *Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer. Colorectal cancer*. 2019; 8(4) CRC11. 12 Nov. 2019, DOI:10.2217/crc-2019-0009.

- Jabłońska-Trypuć, A., Matejczyk, M., & Rosochacki, S. (2016). Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. *Journal of Enzyme Inhibition and Medicinal Chemistry*, *31*(sup1), 177–183. <https://doi.org/10.3109/14756366.2016.1161620>
- Kessenbrock, Kai, Vicki Plaks, and Zena Werb. "Matrix metalloproteinases: regulators of the tumor microenvironment." *Cell* 141.1 (2010): 52-67.
- King, D. E., Matheson, E., Chirina, S., Shankar, A., & Broman-Fulks, J. (2013). The status of baby boomers' health in the United States: the healthiest generation? *JAMA Internal Medicine*, *173*(5), 385–386. <https://doi.org/10.1001/JAMAINTERNMED.2013.2006>
- Komite Penanggulangan Kanker Nasional (KPKN), "Pedoman Nasional Pelayanan Kedokteran Kolorektal" Kementerian Kesehatan Republik Indonesia (2017)
- Koskensalo, S., Hagström, J., Linder, N., Lundin, M., Sorsa, T., Louhimo, J., & Haglund, C. (2012). Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer. *BMC Clinical Pathology*, *12*. <https://doi.org/10.1186/1472-6890-12-24>
- Kostova E, Slaninka-Miceska M, Labacevski N, Jakjovski K, Trojacanec J, Atanasovska E, *et al.* Serum matrix metalloproteinase-2, -7 and -9 (MMP-2, MMP-7, MMP-9) level as prognostic markers in patient with colorectal cancer. *Int J Health Sci.* 2012; 2: 169-75.

- Krizkova, Sona, *et al.* "Assays for determination of matrix metalloproteinases and their activity." *TrAC Trends in Analytical Chemistry* 30.11 (2011): 1819-1832.
- Lee, Chao-Hsien, Shu-Chen Cheng, Hong-Yi Tung, *et al.* *The Risk Factors Affecting Survival in Colorectal Cancer in Taiwan. Iran J Public Health.* 2018; 47(4): pp.519-530.
- Lee, J., Lee, J., & Kim, J. H. (2019). Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer. *Anticancer Research*, 39(11), 5963–5971. <https://doi.org/10.21873/ANTICANRES.13801>
- Liang, S., & Chang, L. (2018). Serum matrix metalloproteinase-9 level as a biomarker for colorectal cancer: a diagnostic meta-analysis. *Biomarkers in Medicine*, 12(4), 393–402. <https://doi.org/10.2217/BMM-2017-0206>
- Liu, Y., Liu, H., Luo, X., Deng, J., Pan, Y., & Liang, H. (2015). Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. *Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine*, 36(6), 4377–4386. <https://doi.org/10.1007/S13277-015-3077-Z>
- Liu, Z., Zhang, Y., Niu, Y., Li, K., Liu, X., Chen, H., & Gao, C. (2014). A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. *PloS One*, 9(8). <https://doi.org/10.1371/JOURNAL.PONE.0103910>

- Maajani, Khadije, *et al.* "Survival rate of colorectal cancer in Iran: a systematic review and meta-analysis." *Asian Pacific journal of cancer prevention: APJCP* 20.1 (2019): 13.
- Martinez-Useros, J., & Garcia-Foncillas, J. (2016). Obesity and colorectal cancer: molecular features of adipose tissue. *Journal of Translational Medicine*, 14(1). <https://doi.org/10.1186/S12967-016-0772-5>
- Matthew Hoffman, MD, *Medically Reviewed by Jennifer Robinson, MD* on June 22, 2020.
- Missiaglia, E., Jacobs, B., D'Ario, G., Di Narzo, A. F., Sonesson, C., Budinska, E., Popovici, V., Vecchione, L., Gerster, S., Yan, P., Roth, A. D., Klingbiel, D., Bosman, F. T., Delorenzi, M., & Tejpar, S. (2014). Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. *Annals of Oncology : Official Journal of the European Society for Medical Oncology*, 25(10), 1995–2001. <https://doi.org/10.1093/ANNONC/MDU275>
- Mondal, S., Adhikari, N., Banerjee, S., Amin, S. A., & Jha, T. (2020). Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. *European Journal of Medicinal Chemistry*, 194. <https://doi.org/10.1016/J.EJMECH.2020.112260>
- Morales-Vásquez, F., Castillo-Sánchez, R., Gómora, M. J., Almaraz, M. Á., Pedernera, E., Pérez-Montiel, D., Rendón, E., López-Basave, H. N., Román-Basaure, E., Cuevas-Covarrubias, S., Maldonado-Cubas, J., Villa, A., & Mendez, C. (2020). Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors.

Journal of Ovarian Research, 13(1). <https://doi.org/10.1186/S13048-020-00676-X>

Mroczo, B., Groblewska, M., Okulczyk, B., Kędra, B., & Szmitkowski, M. (2010).

The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. *International Journal of Colorectal Disease*, 25(10), 1177–1184. <https://doi.org/10.1007/S00384-010-0991-9>

Nasir, A., Kaiser, H. E., Boulware, D., Hakam, A., Zhao, H., Yeatman, T., Barthel,

J., & Coppola, D. (2004). Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. *Clinical Colorectal Cancer*, 3(4), 243–247. <https://doi.org/10.3816/CCC.2004.N.005>

Naylor, R. M., Baker, D. J., & Van Deursen, J. M. (2013). Senescent cells: a novel

therapeutic target for aging and age-related diseases. *Clinical Pharmacology and Therapeutics*, 93(1), 105–116. <https://doi.org/10.1038/CLPT.2012.193>

NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) “Colon Cancer, Rectal Cancer *NCCN Evidence Blocks Version 1.2022*

Otero-Estévez, O., De Chiara, L., Rodríguez-Girondo, M., Rodríguez-Berrocal, F.

J., Cubiella, J., Castro, I., Hernández, V., & Martínez-Zorzano, V. S. (2015). Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening. *Scientific Reports*, 5. <https://doi.org/10.1038/SREP13030>

Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P.,

Passalacqua, R., Sgroi, G., & Barni, S. (2017). Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and

- Meta-analysis. *JAMA Oncology*, 3(2), 211–219.
<https://doi.org/10.1001/JAMAONCOL.2016.4227>
- Pöschl, G., & Seitz, H. K. (2004). Alcohol and cancer. *Alcohol and Alcoholism (Oxford, Oxfordshire)*, 39(3), 155–165.
<https://doi.org/10.1093/ALCALC/AGH057>
- Prasad, S., Sung, B., & Aggarwal, B. B. (2012). Age-associated chronic diseases require age-old medicine: role of chronic inflammation. *Preventive Medicine*, 54 Suppl(Suppl). <https://doi.org/10.1016/J.YPMED.2011.11.011>
- Quan, Taihao, *et al.* "Elevated matrix metalloproteinases and collagen fragmentation in photodamaged human skin: impact of altered extracellular matrix microenvironment on dermal fibroblast function." *The Journal of investigative dermatology*133.5 (2013): 1362.
- Rana AS, *et al.* *Am J Physiol Gastrointest Liver Physiol*. "MMP-9-induced increase in intestinal epithelial tight permeability is mediated by p38 kinase signaling pathway activation of MLCK gene". 2019.
- Recio-Boiles, Alejandro, Abdul Waheed, and Burt Cagir. "Cancer, colon." *StatPearls [Internet]* (2019).
- Rosenbloom J, Macarak E, Piera-Velazquez S, Jimenez SA. *Human Fibrotic Diseases: Current Challenges in Fibrosis Research*. Methods Mol Biol. 2017.
- Shen, H., Yang, J., Huang, Q., Jiang, M. J., Tan, Y. N., Fu, J. F., Zhu, L. Z., Fang, X. F., & Yuan, Y. (2015). Different treatment strategies and molecular features between right-sided and left-sided colon cancers. *World Journal of*


- Gastroenterology*, 21(21), 6470–6478. <https://doi.org/10.3748/WJG.V21.I21.6470>
- Shuryak, I., Sachs, R. K., & Brenner, D. J. (2010). Cancer risks after radiation exposure in middle age. *Journal of the National Cancer Institute*, 102(21), 1628–1636. <https://doi.org/10.1093/JNCI/DJQ346>
- Simon, K. (2016). Colorectal cancer development and advances in screening. *Clinical Interventions in Aging*, 11, 967–976. <https://doi.org/10.2147/CIA.S109285>
- Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H. J. (2017). Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. *European Journal of Cancer (Oxford, England: 1990)*, 84, 69. <https://doi.org/10.1016/J.EJCA.2017.07.016>
- Sun, Jie, *et al.* "The role of m SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer." *BMC cancer*19.1 (2019): 1-10.
- Tahergorabi, Zoya, and Majid Khazaei. "A review on angiogenesis and its assays." *Iranian journal of basic medical sciences* 15.6 (2012): 1110.
- Verma, Rajeshwar P., and Corwin Hansch. "Matrix metalloproteinases (MMPs): chemical–biological functions and (Q) SARs." *Bioorganic & medicinal chemistry* 15.6 (2007): 2223-2268.
- White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Jane Henley, S. (2014). Age and Cancer Risk: A Potentially Modifiable Relationship. *American Journal of Preventive Medicine*, 46(3 0 1), S7. <https://doi.org/10.1016/J.AMEPRE.2013.10.029>
- Wilson, S., Damery, S., Stocken, D. D., Dowswell, G., Holder, R., Ward, S. T.,

- Redman, V., Wakelam, M. J., James, J., Hobbs, F. D. R., & Ismail, T. (2012). Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. *British Journal of Cancer*, *106*(8), 1431. <https://doi.org/10.1038/BJC.2012.93>
- Winer, Arthur, Sylvia Adams, and Paolo Mignatti. "Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes." *Molecular cancer therapeutics* *17.6* (2018): 1147-1155.
- Wong, Martin CS, *et al.* "Prevalence and risk factors of colorectal cancer in Asia." *Intestinal research* *17.3* (2019): 317.
- Yadav, L., Puri, N., Rastogi, V., Satpute, P., Ahmad, R., & Kaur, G. (2014). Matrix metalloproteinases and cancer - Roles in threat and therapy. *Asian Pacific Journal of Cancer Prevention*, *15*(3), 1085–1091. <https://doi.org/10.7314/APJCP.2014.15.3.1085>
- Yamada, Yasuhiro, and Hideki Mori. "Multistep carcinogenesis of the colon in *ApcMin/+* mouse." *Cancer science* *98.1* (2007): 6-10.
- Yang GY, Guo S, Dong CY, Wang XQ, Hu BY, Liu YF. Integrin α V β 6 sustains and promotes tumor invasive growth in colon cancer progression. *World J Gastroenterol*. 2015; *21*: 7457-67.
- Yang, B., Tang, F., Zhang, B., Zhao, Y., Feng, J., & Rao, Z. (2014). Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. *World Journal of Surgical Oncology*, *12*(1), 24. <https://doi.org/10.1186/1477-7819-12-24>
- Zhang, Y., Guan, X. Y., Dong, B., Zhao, M., Wu, J. H., Tian, X. Y., & Hao, C. Y.

(2012). Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features. *Journal of Cancer Research and Clinical Oncology*, 138(12), 2035–2044. <https://doi.org/10.1007/s00432-012-1274-3>

Zuzga, David S., *et al.* "Overexpression of matrix metalloproteinase 9 in tumor epithelial cells correlates with colorectal cancer metastasis." *Clinical and translational science* 1.2 (2008): 136-141.

LAMPIRAN





REKOMENDASI PERSETUJUAN ETIK

Nomor : 90/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 25 Februari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22020057	No Sponsor Protokol	
Peneliti Utama	dr. Mudatsir,SpB	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI MATRIKS METALLOPROTEINASE-9 (MMP-9) DENGAN KLINIKOPATOLOGI PADA PASIEN KANKER KOLOREKTAL		
No Versi Protokol	1	Tanggal Versi	8 Pebruari 2022
No Versi PSP	1	Tanggal Versi	8 Pebruari 2022
Tempat Penelitian	RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 25 Pebruari 2022 sampai 25 Pebruari 2023	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEPK FKUH RSUH dan RSWS	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

PROSEDUR PEMERIKSAAN IMUNOHISTOKIMIA (IHK) DAN MMP-9

- Potong blok paraffin dengan mikrotom pada ketebalan 3-4 μm , lalu celupkan ke dalam *Waterbath*



- Ambil potongan jaringan dengan *slide* lalu tiriskan, dan tulis pada *slide* kode sesuai blok paraffin dengan pensil



- Panaskan *slide* diatas Hot Plate selama 1 jam
- Dinginkan *slide* lalu masukkan kedalam keranjang *slide*
- Deparafinasi (Xylol I, Xylol II, Xylol III) masing-masing 5 menit



- Rehidrasi (Alkohol 96%, Alkohol 80%, Alkohol 70%), masing-masing selama 5 menit, kemudian cuci dengan air mengalir selama 5 menit



- Angkat dari air lalu masukkan *slide* kedalam larutan *Blocking Endogen Peroksida*, rendam selama 15 menit, lalu cuci dengan air mengalir selama 5 menit




- Masukkan keranjang berisi *slide* ke dalam *decloaking* yang berisi larutan *Antigen Retrieval Decloaking Chamber*, lalu letakkan *slide* pada *rack holder* dan masukkan *rack holder* ke dalam *decloaking*, lalu tutup




- Atur waktu yaitu selama 40 menit pada suhu 95 derajat.



- Dinginkan, dengan mengeluarkan *slide* dari *decloaking* dan disimpan pada suhu ruangan
- Setelah dingin , cuci dalam larutan PBS 2x masing-masing selama 5 menit
- Tandai *slide* dengan memberi lingkaran sekitar jaringan
- Atur *slide* pada baki slide
- Ambil satu per satu lalu tetesi *Background Sniper* lalu inkubasi selama 30 menit



- Buang larutan *background sniper* dengan cara ditiriskan pada tisu
- Tetesi Antibodi **MMP-9** lalu inkubasi selama 1 jam pada suhu ruangan
- Cuci PBS 2x selama 5 menit
- Tetesi *Trekkie Universal* lalu diamkan selama 30 menit



- Tiriskan pada tissue lalu tetesi *Trekkavidin-HRP* lalu diamkan selama 30 menit, lalu cuci PBS 2x dengan cara merendam slide selama 5 menit



- Sambil menunggu pencucian, buat larutan DAB dengan cara campurkan cromogen DAB 1 tetes + *Substrat buffer* 1 ml (dicampur dalam tabung bersih) lalu tetesi ke jaringan
- Amati jaringan jika sudah menunjukkan warna coklat, langsung direndam ke dalam air selama 5 menit



- Rendam dengan *hematoxylin Meyer* 5 menit, lalu uci air mengalir selama 5 menit



- Dehidrasi (Alkohol 70%, Alkohol 80%, Alkohol 96%) masing-masing 5 menit, lalu *Clearing* (Xylol I, Xylol II, Xylol III)



- Keringkan slide lalu tetesi dengan entelan lalu tutup dengan *deck glass*.
- Amati di Mikroskop

FOTO KEGIATAN DI LABORATORIUM PATOLOGI ANATOMI

